Evidence map›Paper›PMID 29404958›Full record

ArticleMolecular neurobiology2018

Peripheral and Central Effects of Memantine in a Mixed Preclinical Mice Model of Obesity and Familial Alzheimer's Disease.

Miren Ettcheto, Elena Sánchez-López, Yaiza Gómez-Mínguez, Henrry Cabrera, Oriol Busquets, Carlos Beas-Zarate, Maria Luisa García, Eva Carro, Gemma Casadesus, Carme Auladell and 3 more

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 32 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 3 countries.

Miren EttchetoDepartament de Farmacología, Toxicologia i Quimica Terapéutica, Unitat de Farmacologia i Farmacognosia, Facultat de Farmacia i Ciències de l'Alimentació, Universitat de Barcelona, Av. Joan XXIII s/n, 08028, Barcelona, Spain.
Elena Sánchez-LópezBiomedical Research Networking Center in Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.
Yaiza Gómez-MínguezDepartament de Farmacología, Toxicologia i Quimica Terapéutica, Unitat de Farmacologia i Farmacognosia, Facultat de Farmacia i Ciències de l'Alimentació, Universitat de Barcelona, Av. Joan XXIII s/n, 08028, Barcelona, Spain.
Henrry CabreraDepartament de Farmacología, Toxicologia i Quimica Terapéutica, Unitat de Farmacologia i Farmacognosia, Facultat de Farmacia i Ciències de l'Alimentació, Universitat de Barcelona, Av. Joan XXIII s/n, 08028, Barcelona, Spain.
Oriol BusquetsDepartament de Farmacología, Toxicologia i Quimica Terapéutica, Unitat de Farmacologia i Farmacognosia, Facultat de Farmacia i Ciències de l'Alimentació, Universitat de Barcelona, Av. Joan XXIII s/n, 08028, Barcelona, Spain.
Carlos Beas-ZarateDepartamento de Biología Celular y Molecular, C.U.C.B.A, Universidad de Guadalajara and División de Neurociencias, Sierra Mojada 800, Col. Independencia, 44340, Guadalajara, Jalisco, Mexico.
Maria Luisa GarcíaUnitat de Farmacia, Tecnologia Farmacèutica i Fisico-química, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, Barcelona, Spain.
Eva CarroNeurodegenerative Disorders Group, Instituto de Investigacion Hospital 12 de Octubre (i + 12), Madrid, Spain.
Gemma CasadesusDepartment of Biological Sciences, Kent State University, Kent, OH, USA.
Carme AuladellDepartament de Biologia Cel·lular, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain.
Manuel Vázquez CarreraDepartament de Farmacología, Toxicologia i Quimica Terapéutica, Unitat de Farmacologia i Farmacognosia, Facultat de Farmacia i Ciències de l'Alimentació, Universitat de Barcelona, Av. Joan XXIII s/n, 08028, Barcelona, Spain.
Jaume FolchBiomedical Research Networking Center in Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.
Antoni CaminsDepartament de Farmacología, Toxicologia i Quimica Terapéutica, Unitat de Farmacologia i Farmacognosia, Facultat de Farmacia i Ciències de l'Alimentació, Universitat de Barcelona, Av. Joan XXIII s/n, 08028, Barcelona, Spain. camins@ub.edu.ORCID http://orcid.org/0000-0002-1229-5956
Instituto de Salud Carlos III · ESUniversitat de Barcelona · ESBiomedical Research Networking Center on Neurodegenerative Diseases · ESHospital Sant Joan de Déu Barcelona · ESInstitut de Nanociència i Nanotecnologia de la Universitat de BarcelonaKent State University · USResearch Institute Hospital 12 de Octubre · ESUniversidad de Guadalajara · MX

Funding

NCI CLINICAL INVESTIGATOR AWARD PROGRAMK08CA001023 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI FOGLIA, ROBERT P · 1985 to 1985
–
Agència de Gestió d'Ajuts Universitaris i de Recerca 2014SGR-1023Agència de Gestió d'Ajuts Universitaris i de Recerca 2014SGR-525Spanish Ministry of Science and Innovation CB06/05/0024Spanish Ministry of Science and Innovation MAT 2014-59134-RSpanish Ministry of Science and Innovation PI2016/01
6 · The paper itself

Abstract

There is growing evidence that obesity associated with type 2 diabetes mellitus (T2DM) and aging are risk factors for the development of Alzheimer's disease (AD). However, the molecular mechanisms through which obesity interacts with β-amyloid (Aβ) to promote cognitive decline remains poorly understood. Memantine (MEM), a N-methyl-D-aspartate receptor antagonist, is currently used for the treatment of AD. Nonetheless, few studies have reported its effects on genetic preclinical models of this neurodegenerative disease exacerbated with high-fat diet (HFD)-induced obesity. Therefore, the present research aims to elucidate the effects of MEM on familial AD HFD-induced insulin resistance and learning and memory impairment. Furthermore, it aspires to determine the possible underlying mechanisms that connect AD to T2DM. Wild type and APPswe/PS1dE9 mice were used in this study. The animals were fed with either chow or HFD until 6 months of age, and they were treated with MEM-supplemented water (30 mg/kg) during the last 12 weeks. Our study demonstrates that MEM improves the metabolic consequences produced by HFD in this model of familial AD. Behavioural assessments confirmed that the treatment also improves animals learning abilities and decreases memory loss. Moreover, MEM treatment improves brain insulin signalling upregulating AKT, as well as cyclic adenosine monophosphate response element binding (CREB) expression, and modulates the amyloidogenic pathway, which, in turn, reduced the accumulation of Aβ. Moreover, this drug increases the activation of molecules involved with insulin signalling in the liver, such as insulin receptor substrate 2 (IRS2), which is a key protein regulating hepatic resistance to insulin. These results provide new insight into the role of MEM not only in the occurrence of AD treatment, but also in its potential application on peripheral metabolic disorders where Aβ plays a key role, as is the case of T2DM.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAnimalsBody WeightCognitionDiet, High-FatDisease Models, AnimalFeeding BehaviorGenotypeInflammationInsulinLiverMaleMemantineMice, Inbred C57BLMice, TransgenicAmyloid beta-PeptidesInsulinMemantineAlzheimer’s diseaseAPPswe/PS1dE9DiabetesHigh-fat dietMemantineObesity

Identifiers

PMID29404958
OpenAlexW2786901473

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.